

## ANSWERING REVIEWERS

17<sup>th</sup> of August 2012

Dear Editor,

Please find enclosed the edited manuscript in Word format (file name wjg-2012-033390-review .doc).

**Title: Thiopurines related malignancies in inflammatory bowel disease: Local experience in Granada, Spain**

**Author:** María Gómez-García, Maria José Cabello-Tapia, Antonio Damián Sánchez-Capilla, Javier De Teresa-Galván, Eduardo Redondo-Cerezo

**Manuscript No:** wjg-2012-033390

The manuscript has been improved according to the suggestions of reviewers:


1. Format has been updated
2. Revision has been made according to the suggestions of the reviewer
  - (1) We have added the references supporting our statement: "the use of treatments such as 5-ASA ....reduces the incidence of colorectal cancer", as suggested.
  - (2) We have included a table with a comparison between data from both study groups, patients treated with thiopurines and patients with no thiopurine therapy. As recommended, we have reduce the number of tables.
  - (3) An explanation and a reference regarding Montreal classification have been included.
  - (4) We have included the time of follow-up, the time between diagnosis of IBD, the beginning of therapy with thiopurines and the development of malignancies.
  - (5) We have included the test to measure TPMT activity (HPLC) and its reference levels.
  - (6) Multivariable logistic-regression analyses involving treatment regimen and prespecified baseline characteristics, which were the ones with statistical significance in univariate analyses and also the factors with a potential or already recognized influence on neoplasm development, were performed to evaluate the risk of malignancies. A stepwise procedure was used to identify independent risk factors for neoplasm development (with P=0.05 as the threshold level for variables to be entered into the model and retained in the final model).
  - (7) In the discussion we refer to previous reports which point out this fact. Nevertheless the retrospective and observational design of our database makes impossible to establish such differentiation. We are sorry about this fact, but we cannot perform these statistics with our database.
  - (8) Age included in the logistic regression analysis is the age at diagnosis of IBD.
  - (9) We have replace expressions as "from our unit", "our institution", etc as suggested.
  - (10) We have modified the title as suggested, and within size limits..
  - (11) Changes suggested in the abstract, structural and related to the inclusion of data from our statistics have been included in the revised version.
3. References and typesetting were corrected
5. We have added a running title, a profesional title of the corresponding autor, and a fax number

Thank you again for publishing our manuscript in the *World Journal of Gastroenterology*.


Sincerely yours,



María GÓMEZ-GARCÍA, MD, PhD  
Inflammatory Bowel Disease Unit  
Department of Gastroenterology  
University Hospital Virgen de Las Nieves  
Granada 18014-Spain  
E-mail: mmrosarioes@yahoo.es  
Fax: +34-958-020169



María José CABELLO-TAPIA, MD, PhD  
Inflammatory Bowel Disease Unit  
Department of Gastroenterology  
Hospital Universitario Virgen de Las Nieves  
Granada 18014-Spain  
E-mail:



Antonio Damián SÁNCHEZ-CAPILLA, MD, D  
Department of Gastroenterology  
University Hospital Virgen de Las Nieves  
Granada 18014-Spain  
E-mail: adasanca@hotmail.com



Javier DE TERESA-GALVÁN, MD, PhD  
Department of Gastroenterology  
Hospital Universitario Virgen de Las Nieves  
Granada 18014-Spain  
E-mail:



Eduardo REDONDO-CEREZO, MD, PhD  
Endoscopy Unit  
Department of Gastroenterology  
University Hospital Virgen de Las Nieves  
Granada 18014-Spain  
E-mail: eredondoc@gmail.com